GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at HC Wainwright

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $8.00 target price on the stock.

Several other analysts also recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a research report on Thursday, April 10th. Alliance Global Partners reduced their price objective on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research report on Tuesday. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, GeoVax Labs has a consensus rating of “Buy” and a consensus target price of $12.90.

GeoVax Labs Trading Down 8.1 %

GOVX stock opened at $0.83 on Wednesday. The firm has a market capitalization of $11.48 million, a P/E ratio of -0.15 and a beta of 3.70. GeoVax Labs has a 12 month low of $0.73 and a 12 month high of $11.18. The firm has a 50 day moving average of $1.37 and a 200-day moving average of $1.95.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. Sell-side analysts predict that GeoVax Labs will post -4.49 EPS for the current year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in GeoVax Labs during the third quarter valued at approximately $97,000. Citadel Advisors LLC bought a new position in GeoVax Labs in the 4th quarter worth approximately $104,000. Northern Trust Corp purchased a new position in shares of GeoVax Labs in the fourth quarter worth $29,000. Finally, Geode Capital Management LLC boosted its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after acquiring an additional 33,440 shares during the last quarter. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.